The rebranding effort aims to foster greater consistency as the drugmaker prepares for a significant strategy update scheduled for September 21. By adopting a leaner name, the firm intends to improve its recognition among patients and stakeholders in a sector increasingly shaped by consumer demand for products like its flagship weight-loss drug, Wegovy.

Beyond the name change, management plans to cultivate a more aggressive corporate culture focused on competitiveness. These internal shifts are designed to align with broader business objectives, which executives will detail during the upcoming investor event. For daily operations, the company will transition to the shorter moniker, though Novo Nordisk A/S will persist as the formal global title.